ArticleProceedings of the National Academy of Sciences of the United States of America2011
Adenovirus type-35 vectors block human CD4+ T-cell activation via CD46 ligation.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Biosafety Evaluation of a Chimeric Adenoviral Vector in Mini-Pigs: Insights into Immune Tolerance and Gene Therapy Potential.Biomedicines · 2024Article
- Review
- Construction and application of adenoviral vectors.Molecular therapy. Nucleic acids · 2023Review
- Molecular and cellular changes in the post-traumatic spinal cord remodeling after autoinfusion of a genetically-enriched leucoconcentrate in a mini-pig model.Neural regeneration research · 2023Article
- Induction of Angiogenesis by Genetically Modified Human Umbilical Cord Blood Mononuclear Cells.International journal of molecular sciences · 2023Article
- Autologous Genetically Enriched Leucoconcentrate in the Preventive and Acute Phases of Stroke Treatment in a Mini-Pig Model.Pharmaceutics · 2022Article
- Article
- Gene-modified leucoconcentrate for personalizedNeural regeneration research · 2021Article
- Adenovirus vectors in hematopoietic stem cell genome editing.FEBS letters · 2019Review
- In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia.The Journal of clinical investigation · 2019Article
- Designer Oncolytic Adenovirus: Coming of Age.Cancers · 2018Review
- Clinical features of community acquired adenovirus pneumonia during the 2011 community outbreak in Southern Taiwan: role of host immune response.BMC infectious diseases · 2017Observational
- Viral Manipulation of Host Inhibitory Receptor Signaling for Immune Evasion.PLoS pathogens · 2016Review
- Recombinant Ad35 adenoviral proteins as potent modulators of human T cell activation.Immunology · 2014Article
- Adenovirus serotype 26 and 35 vectors induce simian immunodeficiency virus-specific T lymphocyte responses in foreskin in rhesus monkeys.Journal of virology · 2014Article
- Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures.Gene therapy · 2014Article
- The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.Journal of virology · 2013Article
- Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Article
- The CD46-Jagged1 interaction is critical for human TH1 immunity.Nature immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Recombinant adenoviruses (rAds) based on types 5 (rAd5) and 35 (rAd35) have emerged as important vaccine delivery vectors in clinical testing for a variety of pathogens. A major difference between these vectors is their binding to cellular receptors used for infection. Whereas rAd5 binds coxsackie-adenovirus receptor (CAR), rAd35 binds the complement regulatory protein CD46. Although rAd35 infected and phenotypically matured human blood dendritic cells (DCs) more efficiently than rAd5, we show here that rAd35 markedly suppressed DC-induced activation of naive CD4(+) T cells. rAd35 specifically blocked both DCs and anti-CD3/CD28 mAb-induced naive T-cell proliferation and IL-2 production. This effect was also observed in CD4(+) memory T cells but to a lesser extent. The suppression occurred by rAd35 binding to CD46 on T cells and was independent of infection. CD46 engagement with mAb mimicked the effects of rAd35 and also led to deficient NF-κB nuclear translocation. In contrast, rAd5 and rAd35 vectors with ablated CD46 binding did not inhibit T-cell activation. Our findings provide insights into the basic biology of adenoviruses and indicate that CD46 binding may have an impact on the generation of primary CD4(+) T-cell responses by Ad35.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.